PharmaCyte Biotech Faces Nasdaq Delisting Risk Over Bid Price Rule Compliance
PharmaCyte Biotech Inc. faces a risk of delisting from Nasdaq due to non-compliance with the minimum bid price requirement of $1.00 per share. The company has until June 1, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 per share for 10 consecutive business days. Failure to comply may lead to delisting, though an extension is possible if other listing requirements are met.
PharmaCyte Biotech Inc. has received a notice from the Nasdaq Stock Market indicating non-compliance with the minimum bid price requirement of $1.00 per share, as outlined in Nasdaq Listing Rule 5550(a)(2). The company now has 180 calendar days, until June 1, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. If compliance is not achieved within this period, PharmaCyte may be eligible for an additional 180-day extension if other initial listing requirements are met. Failure to regain compliance could result in the company’s securities being delisted from the Nasdaq Capital Market. The notice does not affect the company’s business operations or its SEC reporting obligations. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PharmaCyte Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-25-008947), on December 05, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
